Literature DB >> 25636464

Mouse models of breast cancer.

Kazuhito Sakamoto1, Jeffrey W Schmidt, Kay-Uwe Wagner.   

Abstract

Breast cancer is the most common cause of cancer death in women worldwide. This malignancy is a complex disease, which is defined by an intrinsic heterogeneity on the histopathological and molecular level as well as response to therapy and outcome. In addition to classical histopathological features, breast cancer can be categorized into at least five major subtypes based on comprehensive gene expression profiling: luminal A, luminal B, basal-like, ERBB2-positive, and normal-like breast cancer. Genetically engineered mouse models can serve as tools to study the molecular underpinnings for this disease. Given the genetic complexity that drives the initiation and progression of individual breast cancer subtypes, it is evident that certain models can reflect only particular aspects of this malignancy. In this book chapter, we will primarily focus on advances in modeling breast cancer at defined stages of carcinogenesis using genetically engineered mice. We will discuss the ability as well as shortcomings of these models to faithfully recapitulate the spectrum of human breast cancer subtypes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25636464      PMCID: PMC6492279          DOI: 10.1007/978-1-4939-2297-0_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  10 in total

1.  Ecdysoneless Overexpression Drives Mammary Tumorigenesis through Upregulation of C-MYC and Glucose Metabolism.

Authors:  Bhopal C Mohapatra; Sameer Mirza; Aditya Bele; Channabasavaiah B Gurumurthy; Mohsin Raza; Irfana Saleem; Matthew D Storck; Aniruddha Sarkar; Sai Sundeep Kollala; Surendra K Shukla; Siddesh Southekal; Kay-Uwe Wagner; Fang Qiu; Subodh M Lele; Mansour A Alsaleem; Emad A Rakha; Chittibabu Guda; Pankaj K Singh; Robert D Cardiff; Hamid Band; Vimla Band
Journal:  Mol Cancer Res       Date:  2022-09-02       Impact factor: 6.333

2.  Identification of early biomarkers in saliva in genetically engineered mouse model C(3)1-TAg of breast cancer.

Authors:  Isadora Fernandes Gilson Sena; Larissa Lessi Fernandes; Leonardo Lima Lorandi; Thais Viggiani Santana; Luciana Cintra; Ismael Feitosa Lima; Leo Kei Iwai; Jill M Kramer; Alexander Birbrair; Débora Heller
Journal:  Sci Rep       Date:  2022-07-07       Impact factor: 4.996

3.  C(3)1-TAg in C57BL/6 J background as a model to study mammary tumor development.

Authors:  Isadora F G Sena; Beatriz G S Rocha; Caroline C Picoli; Gabryella S P Santos; Alinne C Costa; Bryan O P Gonçalves; Ana Paula V Garcia; Maryam Soltani-Asl; Leda M C Coimbra-Campos; Walison N Silva; Pedro A C Costa; Mauro C X Pinto; Jaime H Amorim; Vasco A C Azevedo; Rodrigo R Resende; Debora Heller; Geovanni D Cassali; Akiva Mintz; Alexander Birbrair
Journal:  Histochem Cell Biol       Date:  2021-05-18       Impact factor: 4.304

Review 4.  Emerging roles of DYRK2 in cancer.

Authors:  Vasudha Tandon; Laureano de la Vega; Sourav Banerjee
Journal:  J Biol Chem       Date:  2021-01-07       Impact factor: 5.157

5.  Postponing tumor onset and tumor progression can be achieved by alteration of local tumor immunity.

Authors:  Yan Mei; Mingdian Wang; Guanming Lu; Jiangchao Li; Lixia Peng; Yanhong Lang; Mingming Yang; Lingbi Jiang; Changzhi Li; Lisheng Zheng; Zhijie Liu; Dehuan Xie; Lingling Guo; Bijun Huang; Musheng Zeng; Yanxia Shi; Chaonan Qian
Journal:  Cancer Cell Int       Date:  2021-02-10       Impact factor: 5.722

6.  Combined Ultrasound Treatment with Transferrin-Coupled Nanoparticles Improves Active Targeting of 4T1 Mammary Carcinoma Cells.

Authors:  Xiangzi Jin; Jie Yu; Meijiao Yin; Amit Sinha; Guangming Jin
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

7.  Dual recombinase action in the normal and neoplastic mammary gland epithelium.

Authors:  Patrick D Rädler; Kerry Vistisen; Aleata A Triplett; Rayane Dennaoui; Yong Li; Hridaya Shrestha; Rosa-Maria Ferraiuolo; Amalraj Thangasamy; Dieter Saur; Kay-Uwe Wagner
Journal:  Sci Rep       Date:  2021-10-21       Impact factor: 4.379

8.  BRCA1/2 Serves as a Biomarker for Poor Prognosis in Breast Carcinoma.

Authors:  Tong Yi Jin; Kyoung Sik Park; Sang Eun Nam; Young Bum Yoo; Won Seo Park; Ik Jin Yun
Journal:  Int J Mol Sci       Date:  2022-03-29       Impact factor: 5.923

Review 9.  Engineering Breast Cancer On-chip-Moving Toward Subtype Specific Models.

Authors:  Carmen Moccia; Kristina Haase
Journal:  Front Bioeng Biotechnol       Date:  2021-06-23

10.  Conversion of a Non-Cancer-Selective Promoter into a Cancer-Selective Promoter.

Authors:  Praveen Bhoopathi; Anjan K Pradhan; Amit Kumar; Santanu Maji; Padmanabhan Mannangatti; Xiaoyan Deng; Dipankar Bandyopadhyay; Devanand Sarkar; Xiang-Yang Wang; Joseph W Landry; Swadesh K Das; Luni Emdad; Paul B Fisher
Journal:  Cancers (Basel)       Date:  2022-03-15       Impact factor: 6.575

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.